Novel protein may improve safety of therapy for pancreatic cancer

Novel protein may improve safety of therapy for pancreatic cancer

Photo credit: iStock

LONDON

Researchers have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.

Using this protein as a target, the team successfully created a CAR T cell therapy -- a type of immunotherapy -- that killed pancreatic cancer cells in a pre-clinical model.

"This is an exciting development," said John Marshall, Professor from Queen Mary University of London.

"Finding that CEACAM7 allows us to kill pancreatic cancer cells specifically with CAR T cells while having no significant toxicity in non-tumour tissues, gives us hope that this strategy could be effective in the future," Marshall added.

CAR T cell therapy is an immunotherapy that has shown great promise for the treatment of some blood cancers; however, the treatment of solid tumours using this therapy has proved very difficult.

One barrier to success is toxicity in tissues other than the cancer because most of the proteins currently used to target CAR T cells to pancreatic cancer cells and other solid tumours are present in low levels on other normal tissues, leading to toxic side effects, the researchers said.

In this study, published in the journal Clinical Cancer Research, the team identified a protein called CEACAM7 that may represent a safer treatment target for the development of therapies against pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.

By using a specialised technique called immunostaining, the team examined a panel of human PDAC samples, and normal tissues for the presence of CEACAM7.

A large subset of PDAC samples tested expressed CEACAM7, but the protein was undetectable in a panel of normal tissues including tonsil, lung, liver, and prostate, suggesting that CEACAM7 may be an ideal target for CAR T cell development against pancreatic cancer.

To determine the potential of CEACAM7 as a treatment target, the team developed CAR T cells targeted to CEACAM7 and applied these to PDAC cell lines as well as a preclinical model of PDAC.

The CAR T cells effectively targeted the CEACAM7-expressing cells in PDAC cell cultures, and eliminated cancer cells in a late-stage preclinical model of PDAC.

---IANS

Top Stories

Punjab, 5 other states account for over 85 per cent of fresh Covid cases

Punjab, 5 other states account for over 85 per cent of fresh Covid cases

A total of 17,407 new infections have been registered in a d...

Navjot Sidhu again corners Amarinder govt, wants fresh laws to counter central farm Bills

Navjot Sidhu again corners Amarinder govt, wants fresh laws to counter central farm Bills

Hits out at Centre over three farm Bills, calls them 'illega...

EPFO fixes 8.5 per cent interest on EPF deposits for 2020-21

EPFO fixes 8.5 per cent interest on EPF deposits for 2020-21

EPFO has more than five crore active subscribers

IED blast in Jharkhand kills 3 security personnel

IED blast in Jharkhand kills 3 security personnel

A jawan of the Jharkhand Jaguars and a Central Reserve Polic...

Opposition MLAs showed disrespect to national flag while banging on bonnet of Guv’s car: Jai Ram Thakur

Opposition MLAs showed disrespect to national flag while banging on bonnet of Guv’s car: Jai Ram Thakur

Members of the Congress did not attend the proceedings on Th...

Cities

View All